Publications by authors named "F Zanzi"
Article Synopsis
- This study compares two surgical methods, Hartmann's procedure (HP) and resection with primary anastomosis (RPA), for treating acute left-sided colonic emergencies among 1215 patients from 204 centers globally.
- Results showed that while HP was the more common treatment (57.3%), RPA was favored for younger patients with fewer health issues and those needing surgery sooner.
- The study concluded that although HP is still widely used, RPA might be the better option, emphasizing the importance of patient characteristics and surgeon experience in determining treatment choice.
The presence of sarcopenia has been associated with the worst outcome of Crohn's disease (CD). At present, no studies have evaluated the impact of ustekinumab (UST) in terms of its effects on body composition. The aim of this prospective study was to evaluate whether UST treatment could modify the parameters of body composition as assessed by bioelectrical impedance assay (BIA) in patients with CD.
View Article and Find Full Text PDFThe tripartite complex AcrAB-TolC is the major RND pump in and other Enterobacteriaceae, including , the etiological agent of bacillary dysentery. In addition to conferring resistance to many classes of antibiotics, AcrAB plays a role in the pathogenesis and virulence of several bacterial pathogens. Here, we report data demonstrating that AcrAB specifically contributes to invasion of epithelial cells.
View Article and Find Full Text PDFArticle Synopsis
- The ChoCO-W study aimed to examine the effects of COVID-19 on the clinical presentation and outcomes of acute cholecystitis, particularly focusing on the rise of gangrenous cases during the pandemic.
- Over 2,800 patients from 42 countries were enrolled, with a notable 6.9% testing positive for COVID-19, revealing a significantly higher prevalence of preexisting conditions and more severe outcomes in this group compared to those without the virus.
- Patients with COVID-19 experienced higher postoperative complications (32.2% vs. 11.7%), longer hospital stays (13.21 days vs. 6.51 days), increased mortality rates (13.4% vs. 1.7
Article Synopsis
- Oncostatin M is a helpful blood marker that can show how well certain medicines work for people with inflammatory bowel diseases (IBD), especially when using anti-TNF drugs like infliximab.
- The study looked at two groups of IBD patients to see how well their treatment worked after 54 weeks, measuring oncostatin M and other markers in their blood and stool.
- Results showed that lower levels of oncostatin M before treatment were linked to better healing in patients taking anti-TNF drugs, but not in those on vedolizumab, indicating that oncostatin M is useful for predicting treatment success with anti-TNF medications.